The Translational Research Institute (TRI) is a ground breaking, industry leading initiative in the Australian medical research field – bringing four of the country’s pinnacle research facilities together with the aim of improving and accelerating medical research and translating that research into greater palliative care. The TRI will allow – for the first time in Australia – biopharmaceuticals and treatments to be discovered, produced, clinically tested and manufactured in one location.
The TRI will focus on a wide range of health and medical research areas including cervical cancer, prostate cancer, breast cancer, melanoma, liver and kidney disease, malaria, HIV, osteoporosis, obesity, arthritis and diabetes.
The TRI is a joint venture between the University of Queensland’s Diamantina Institute, Queensland University of Technology’s Institute of Health and Biomedical Innovation, Mater Medical Research Institute (MMRI) and the Princess Alexandra Hospital’s Centres for Health Research. The TRI has been made possible through $354 million in funding which was provided by the Australian and Queensland Governments, The Atlantic Philanthropies, UQ and QUT.
The centre was the vision of 2006 Australian of the Year Professor Ian Frazer – inventor of the cervical cancer vaccine (HPV) – and the Mater Medical Research Institute (MMRI).
The TRI will combine academic medicine and translational research, in order to minimise the time between a laboratory discovery and its effective application in the clinic and the community.